Latanoprost & brinzolamide offer 24-hour IOP reductions

Article

The combination of latanoprost and brinzolamide for the treatment of normal-tension glaucoma (NTG) can successfully lower intraocular pressure (IOP) both during the day and at night.

The combination of latanoprost and brinzolamide for the treatment of normal-tension glaucoma (NTG) can successfully lower intraocular pressure (IOP) both during the day and at night, according to a report published in the June/July issue of the Journal of Glaucoma.

Kenji Nakamoto and Noriko Yasuda form the Tokyo Metropolitan Police Hospital, Tokyo, Japan conducted a study to assess the 24-hour variation in IOP seen in NTG patients being treated with the latanoprost/brinzolamide combination. A total of 44 eyes (22 subjects) were included and a mean 24-hour IOP variation was determined after a washout period of >/=4 weeks.

Latanoprost monotherapy was continued in both eyes for eight weeks and then patients were randomized to continue latanoprost in one eye and brinzolamide in the other. After eight-weeks follow-up, the 24-hour IOP variation was re-measured, eight times daily in the sitting position before and after treatment.

Both groups, those on latanoprost and those on the combination therapy, showed a significant decrease in IOP at all time points, however, those in the combination group demonstrated more significant mean decreases in nocturnal and diurnal IOP.

The researchers concluded that the combination treatment is more successful in lowering IOP over a 24-hour period than latanoprost alone.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.